Ipatasertib / GDC-0068

Target: AKT | Indication: Solid Tumors

Introduction / Brief Description

Ipatasertib is an AKT inhibitor invented by Array under a collaboration agreement with Genentech. Array has received certain clinical milestones and is entitled to additional potential clinical and commercial milestones and royalties on product sales under the agreement.

AKT activity is frequently elevated in cancer via multiple mechanisms, including loss of function of the PTEN tumor suppressor gene or mutations/amplifications of the PIK3CA or AKT genes. AKT pathway activation is associated with poor prognosis and may lead to resistance to chemotherapy. Ipatasertib is advancing in clinical development including a Phase 3 trial in patients with prostate cancer and three Phase 2 trials in patients with breast cancer, gastric cancer and prostate cancer.

Clinical Trials

To learn more about Ipatasertib clinical trials, click here.


Ipatasertib / Cancer


International Society for the Study of Xenobiotics North American Regional Meeting

Preclinical ADME Evaluation of GDC-0068, a Novel, ATP-competitive Akt Inhibitor

B. M. Liederer, et al

Ipatasertib / Cancer


European Society for Medical Oncology Congress

Phase Ib Dose Escalation Study of the Akt Inhibitor GDC-0068 with Docetaxel or mFOLFOX6 in Patients with Advanced Solid Tumors

J.C. Bendell, et al.

Ipatasertib / Cancer


Journal of Medicinal Chemistry

Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors

J. F. Blake, et al.